Drugs / Visbiome Extra Strength
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02903030 | Aug 2016 → Dec 2017 | anxiety, autism spectrum disorder | Ohio State University | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02706717 Comparator | Apr 2016 → Jun 2017 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Visbiome Extra Strength | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02903030 ↗ |
| Modality | Other / unclassified | “after 24 weeks of probiotic Visbiome Extra Strength (ES) therapy” NCT02706717 ↗ |
| Route | Oral | “participant will receive one sachet orally daily” NCT02706717 ↗ |